Ashar Bhavesh 4

What Happened

• Ashar Bhavesh, Chief Operating Officer of Tyra Biosciences (TYRA), received equity awards on May 5, 2026 totaling 65,308 units: 15,013 restricted stock units (RSUs) and 50,295 derivative awards. All grants were reported with an acquisition price of $0.00 (no cash paid at grant).

Key Details

• Transaction date(s): May 5, 2026; Form 4 filed May 7, 2026 (appears timely — within the usual 2-business-day window).
• Reported amounts: 15,013 RSUs (footnote F1) + 50,295 derivative awards = 65,308 total.
• Reported price/value: $0.00 per share/unit at grant (standard for equity compensation grants).
• Shares owned after transaction: Not specified in the provided excerpt.
• Footnotes:
  • F1: The 15,013 RSUs vest 25% on each of the first four anniversaries of May 5, 2026, subject to continued service; each RSU converts to one share upon vesting.
  • F2: Indicates some reported amounts include RSUs.
  • F3: Describes a standard option vesting schedule — 25% vests on May 5, 2027, then 1/48th monthly thereafter (applies to option-style derivative awards).

Context

• RSUs are a form of compensation that convert to shares only if and when they vest; they do not require purchase price at grant. Option-style derivative awards require vesting (and later exercise) before becoming shares and may require payment to acquire stock.
• Grants like these are routine executive compensation and are informational rather than a direct market signal of buying or selling.